A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the primary study objectives and indicators, and plans to enroll about 50-60 patients.

Study Overview

• Status: Active, not recruiting
• Conditions: Advanced Hepatocellular Carcinoma (HCC)
• Intervention / Treatment: Combination product: Toripalimab combined with Bevacizumab

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Beijing Cancer Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

"The patients meeting all the following inclusion criteria can be enrolled in this study:

1. Age of 18-70 years (inclusive), male or female.
2. HCC diagnosed by histopathological examination or Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition).
3. Stage B (middle stage) or C (late stage) HCC determined in accordance with Barcelona Clinic Liver Cancer staging system (BCLC stage). In case of stage B, the patient must be unsuitable for surgery and/or local therapy, or have progressive disease after surgery and/or local therapy, or refuse surgery and/or local therapy (special instruction and signature required).
4. No previous use of any systemic therapy or HCC.
5. Having ≥ 1 measurable lesion in accordance with RECISTv1.1.
6. Grade A Child-Pugh hepatic function, with no history of hepatic encephalopathy.
7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-1.
8. Expected survival ≥12 weeks.
9. Adequate hematologic and end-organ function..
10. In case of HBsAg (+) and/or HBcAb (+), HBV DNA is required to be < 500 IU/mL, and it is required to continue the effective anti-HBV therapy that has been adopted in the full course, or start to use Entecavir or tenofovir in the full course during the study. HBV/HCV co-infected patients will be excluded. Patients with a history of HCV infection but with negative HCV RNA PCR results can be considered uninfected with HCV.
11. Female patients of childbearing potential must receive serum pregnancy test within 7 days before enrollment, have negative result, and agree to use reliable and effective contraceptive methods during the trial and within 60 days after the last dose of study drug. The male patients whose partners are women of childbearing potential must agree to use reliable and effective contraceptive methods during the trial and within 60 days after the last dose of study drug.
12. Being voluntary to participate in the study, sufficiently informed consent and signature of written informed consent form, with good compliance.

Patients can not be enrolled in the study if any one of the following criteria is fulfilled:

1. Known cholangiocellular carcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma and hepatic fibrolamellar carcinoma.
2. Malignant tumor except HCC in the past 5 years: however, localized tumor cured in the study is excluded, including cervical carcinoma in situ, skin basal cell carcinoma and carcinoma in situ of prostate.
3. Hepatic surgery and/or local therapy or treatment with investigational product for HCC within 4 weeks prior to enrollment; palliative therapy for bone metastatic lesion within 2 weeks prior to enrollment. Toxicity reaction induced by previous therapy (except alopecia) not recovered to ≤ grade 1 (NCI-CTCAE v5.0). Chinese medicine preparation with anti-liver cancer effect within 2 weeks prior to enrollment.
4. Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious moderate peritoneal effusion at screening,
5. History of gastrointestinal hemorrhage within 6 months prior to enrollment; the patients with portal hypertension need to receive gastroscopy to exclude the patients with "red sign", if they are considered by investigators to have high risk for hemorrhage . The patient needs to be excluded if there is a history of "red sign" in gastroscopy.
6. Having ≥ grade 3 (NCI-CTCAE v5.0) gastrointestinal or non-gastrointestinal fistula at present.
7. Patients with cancer thrombus in the main trunk of portal vein (Vp4), or cancer thrombus in inferior vena cava should be excluded. However, the patients with cancer thrombus in the main trunk of portal vein but unobstructed branch of contralateral portal vein are allowed to be enrolled.
8. Previous history of serious cardiovascular and cerebrovascular diseases:
9. Having major bleeding and coagulation disorders or other obvious evidence on hemorrhagic tendency:
10. Medium to large surgical treatment within 4 weeks prior to enrollment, however, not including diagnostic biopsy.
11. Central nervous system metastasis.
12. Serious, uncured wound, active ulcer or untreated bone fracture.
13. Vaccination of live vaccine within 30 days prior to enrollment.
14. Active autoimmune diseases requiring systemic treatment (i.e., immunomodulatory drug, corticosteroid or immunosuppressant) in the past 2 years; however, replacement therapy (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy for renal or pituitary insufficiency) will not be considered as systemic therapy and is allowed to be used, and enrollment is allowed.
15. History of clear interstitial lung disease or non-infectious pneumonia, unless induced by local radiotherapy; history of active tuberculosis.
16. Any serious acute and chronic infection requiring systemic antibacterial, antifungal or antiviral therapy at screening, not including viral hepatitis.
17. Known history of human immunodeficiency virus (HIV) infection.
18. Previously receiving allogeneic stem cell or solid organ transplantation.

20. Known history of serious allergy to any monoclonal antibody, anti-angiogenesis targeted drug.

"

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Single Arm; Experimental group: Toripalimab combined with Bevacizumab	Combination product: Toripalimab combined with Bevacizumab; Experimental group: Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	The rate of participants that achieve either a complete response (CR) or a partial response (PR).	Up to 2 years
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Frequency table will be used to summarize occurrence of each treatment-emergent AE	Up to 2 years
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Number and incidence of abnormal laboratory examinations by treatment group.	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
DoR	The time from the first assessment of CR or PR to the first assessment of PD or death due to any cause.	Up to 2 years
DCR	The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable.	Up to 2 years
TTP	time from the start of treatment to progression of diease.	Up to 2 years
PFS	PFS is defined as time from the start of treatment to progression of disease or death.	Up to 2 years
Overall survival (OS)	Overall survival is defined as time from the start of treatment until death due to any reason.	Up to 2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
PD-L1	Correlation between PD-L1 expression level in tumor tissue, proportion of strong positive expression of PD-L1	Up to 2 years
TMB	Correlation betweenTumor mutation burden (TMB) and the efficacy	Up to 2 years
PK	Pharmacokinetic profile in HCC patients of observed maximum plasma concentration	Up to 2 years
ADA	Analysis of anti-drug antibody (ADA) during treatment.	Up to 2 years

Collaborators and Investigators

• Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 10, 2020
• Primary Completion (ACTUAL): December 22, 2020
• Study Completion (ANTICIPATED): December 31, 2022

Study Registration Dates

• First Submitted: September 22, 2020
• First Submitted That Met QC Criteria: October 21, 2020
• First Posted (ACTUAL): October 28, 2020

Study Record Updates

• Last Update Posted (ACTUAL): November 24, 2021
• Last Update Submitted That Met QC Criteria: November 22, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Bevacizumab
• Other Study ID Numbers: JS001-034-II-HCC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No